Global Human Granulocyte Colony-stimulating Factor Market Research Report 2023

Report ID: 1900806 | Published Date: Jan 2025 | No. of Page: 108 | Base Year: 2024 | Rating: 4.3 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Human Granulocyte Colony-stimulating Factor Market Overview
    1.1 Product Overview and Scope of Human Granulocyte Colony-stimulating Factor
    1.2 Human Granulocyte Colony-stimulating Factor Segment by Type
        1.2.1 Global Human Granulocyte Colony-stimulating Factor Sales Growth Rate Comparison by Type (2022-2028)
        1.2.2 300μg/Dose
        1.2.3 150μg/Dose
        1.2.4 75μg/Dose
        1.2.5 Others
    1.3 Human Granulocyte Colony-stimulating Factor Segment by Application
        1.3.1 Global Human Granulocyte Colony-stimulating Factor Sales Comparison by Application: (2022-2028)
        1.3.2 Hospital
        1.3.3 Clinic
    1.4 Global Human Granulocyte Colony-stimulating Factor Market Size Estimates and Forecasts
        1.4.1 Global Human Granulocyte Colony-stimulating Factor Revenue 2017-2028
        1.4.2 Global Human Granulocyte Colony-stimulating Factor Sales 2017-2028
        1.4.3 Human Granulocyte Colony-stimulating Factor Market Size by Region: 2017 Versus 2021 Versus 2028
2 Human Granulocyte Colony-stimulating Factor Market Competition by Manufacturers
    2.1 Global Human Granulocyte Colony-stimulating Factor Sales Market Share by Manufacturers (2017-2022)
    2.2 Global Human Granulocyte Colony-stimulating Factor Revenue Market Share by Manufacturers (2017-2022)
    2.3 Global Human Granulocyte Colony-stimulating Factor Average Price by Manufacturers (2017-2022)
    2.4 Manufacturers Human Granulocyte Colony-stimulating Factor Manufacturing Sites, Area Served, Product Type
    2.5 Human Granulocyte Colony-stimulating Factor Market Competitive Situation and Trends
        2.5.1 Human Granulocyte Colony-stimulating Factor Market Concentration Rate
        2.5.2 The Global Top 5 and Top 10 Largest Human Granulocyte Colony-stimulating Factor Players Market Share by Revenue
        2.5.3 Global Human Granulocyte Colony-stimulating Factor Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Human Granulocyte Colony-stimulating Factor Retrospective Market Scenario by Region
    3.1 Global Human Granulocyte Colony-stimulating Factor Retrospective Market Scenario in Sales by Region: 2017-2022
    3.2 Global Human Granulocyte Colony-stimulating Factor Retrospective Market Scenario in Revenue by Region: 2017-2022
    3.3 North America Human Granulocyte Colony-stimulating Factor Market Facts & Figures by Country
        3.3.1 North America Human Granulocyte Colony-stimulating Factor Sales by Country
        3.3.2 North America Human Granulocyte Colony-stimulating Factor Revenue by Country
        3.3.3 U.S.
        3.3.4 Canada
    3.4 Europe Human Granulocyte Colony-stimulating Factor Market Facts & Figures by Country
        3.4.1 Europe Human Granulocyte Colony-stimulating Factor Sales by Country
        3.4.2 Europe Human Granulocyte Colony-stimulating Factor Revenue by Country
        3.4.3 Germany
        3.4.4 France
        3.4.5 U.K.
        3.4.6 Italy
        3.4.7 Russia
    3.5 Asia Pacific Human Granulocyte Colony-stimulating Factor Market Facts & Figures by Region
        3.5.1 Asia Pacific Human Granulocyte Colony-stimulating Factor Sales by Region
        3.5.2 Asia Pacific Human Granulocyte Colony-stimulating Factor Revenue by Region
        3.5.3 China
        3.5.4 Japan
        3.5.5 South Korea
        3.5.6 India
        3.5.7 Australia
        3.5.8 Taiwan
        3.5.9 Indonesia
        3.5.10 Thailand
        3.5.11 Malaysia
        3.5.12 Philippines
        3.5.13 Vietnam
    3.6 Latin America Human Granulocyte Colony-stimulating Factor Market Facts & Figures by Country
        3.6.1 Latin America Human Granulocyte Colony-stimulating Factor Sales by Country
        3.6.2 Latin America Human Granulocyte Colony-stimulating Factor Revenue by Country
        3.6.3 Mexico
        3.6.4 Brazil
        3.6.5 Argentina
    3.7 Middle East and Africa Human Granulocyte Colony-stimulating Factor Market Facts & Figures by Country
        3.7.1 Middle East and Africa Human Granulocyte Colony-stimulating Factor Sales by Country
        3.7.2 Middle East and Africa Human Granulocyte Colony-stimulating Factor Revenue by Country
        3.7.3 Turkey
        3.7.4 Saudi Arabia
        3.7.5 UAE
4 Global Human Granulocyte Colony-stimulating Factor Historic Market Analysis by Type
    4.1 Global Human Granulocyte Colony-stimulating Factor Sales Market Share by Type (2017-2022)
    4.2 Global Human Granulocyte Colony-stimulating Factor Revenue Market Share by Type (2017-2022)
    4.3 Global Human Granulocyte Colony-stimulating Factor Price by Type (2017-2022)
5 Global Human Granulocyte Colony-stimulating Factor Historic Market Analysis by Application
    5.1 Global Human Granulocyte Colony-stimulating Factor Sales Market Share by Application (2017-2022)
    5.2 Global Human Granulocyte Colony-stimulating Factor Revenue Market Share by Application (2017-2022)
    5.3 Global Human Granulocyte Colony-stimulating Factor Price by Application (2017-2022)
6 Key Companies Profiled
    6.1 Chugai Pharmaceutical
        6.1.1 Chugai Pharmaceutical Corporation Information
        6.1.2 Chugai Pharmaceutical Description and Business Overview
        6.1.3 Chugai Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2017-2022)
        6.1.4 Chugai Pharmaceutical Human Granulocyte Colony-stimulating Factor Product Portfolio
        6.1.5 Chugai Pharmaceutical Recent Developments/Updates
    6.2 Kyowa Hakko Kirin
        6.2.1 Kyowa Hakko Kirin Corporation Information
        6.2.2 Kyowa Hakko Kirin Description and Business Overview
        6.2.3 Kyowa Hakko Kirin Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2017-2022)
        6.2.4 Kyowa Hakko Kirin Human Granulocyte Colony-stimulating Factor Product Portfolio
        6.2.5 Kyowa Hakko Kirin Recent Developments/Updates
    6.3 Sanway
        6.3.1 Sanway Corporation Information
        6.3.2 Sanway Description and Business Overview
        6.3.3 Sanway Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2017-2022)
        6.3.4 Sanway Human Granulocyte Colony-stimulating Factor Product Portfolio
        6.3.5 Sanway Recent Developments/Updates
    6.4 GenSci
        6.4.1 GenSci Corporation Information
        6.4.2 GenSci Description and Business Overview
        6.4.3 GenSci Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2017-2022)
        6.4.4 GenSci Human Granulocyte Colony-stimulating Factor Product Portfolio
        6.4.5 GenSci Recent Developments/Updates
    6.5 SL PHARM
        6.5.1 SL PHARM Corporation Information
        6.5.2 SL PHARM Description and Business Overview
        6.5.3 SL PHARM Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2017-2022)
        6.5.4 SL PHARM Human Granulocyte Colony-stimulating Factor Product Portfolio
        6.5.5 SL PHARM Recent Developments/Updates
    6.6 Kexing Bioproducts
        6.6.1 Kexing Bioproducts Corporation Information
        6.6.2 Kexing Bioproducts Description and Business Overview
        6.6.3 Kexing Bioproducts Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2017-2022)
        6.6.4 Kexing Bioproducts Human Granulocyte Colony-stimulating Factor Product Portfolio
        6.6.5 Kexing Bioproducts Recent Developments/Updates
    6.7 Qilu Pharmaceutical
        6.6.1 Qilu Pharmaceutical Corporation Information
        6.6.2 Qilu Pharmaceutical Description and Business Overview
        6.6.3 Qilu Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2017-2022)
        6.4.4 Qilu Pharmaceutical Human Granulocyte Colony-stimulating Factor Product Portfolio
        6.7.5 Qilu Pharmaceutical Recent Developments/Updates
    6.8 CSPC
        6.8.1 CSPC Corporation Information
        6.8.2 CSPC Description and Business Overview
        6.8.3 CSPC Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2017-2022)
        6.8.4 CSPC Human Granulocyte Colony-stimulating Factor Product Portfolio
        6.8.5 CSPC Recent Developments/Updates
    6.9 Wuzhong Pharmaceutical
        6.9.1 Wuzhong Pharmaceutical Corporation Information
        6.9.2 Wuzhong Pharmaceutical Description and Business Overview
        6.9.3 Wuzhong Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2017-2022)
        6.9.4 Wuzhong Pharmaceutical Human Granulocyte Colony-stimulating Factor Product Portfolio
        6.9.5 Wuzhong Pharmaceutical Recent Developments/Updates
    6.10 Quangang Pharmaceutical
        6.10.1 Quangang Pharmaceutical Corporation Information
        6.10.2 Quangang Pharmaceutical Description and Business Overview
        6.10.3 Quangang Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2017-2022)
        6.10.4 Quangang Pharmaceutical Human Granulocyte Colony-stimulating Factor Product Portfolio
        6.10.5 Quangang Pharmaceutical Recent Developments/Updates
    6.11 Huabei Pharmaceutical
        6.11.1 Huabei Pharmaceutical Corporation Information
        6.11.2 Huabei Pharmaceutical Human Granulocyte Colony-stimulating Factor Description and Business Overview
        6.11.3 Huabei Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2017-2022)
        6.11.4 Huabei Pharmaceutical Human Granulocyte Colony-stimulating Factor Product Portfolio
        6.11.5 Huabei Pharmaceutical Recent Developments/Updates
    6.12 Harbin Pharmaceutical
        6.12.1 Harbin Pharmaceutical Corporation Information
        6.12.2 Harbin Pharmaceutical Human Granulocyte Colony-stimulating Factor Description and Business Overview
        6.12.3 Harbin Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2017-2022)
        6.12.4 Harbin Pharmaceutical Human Granulocyte Colony-stimulating Factor Product Portfolio
        6.12.5 Harbin Pharmaceutical Recent Developments/Updates
    6.13 Amoytop Biotech
        6.13.1 Amoytop Biotech Corporation Information
        6.13.2 Amoytop Biotech Human Granulocyte Colony-stimulating Factor Description and Business Overview
        6.13.3 Amoytop Biotech Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2017-2022)
        6.13.4 Amoytop Biotech Human Granulocyte Colony-stimulating Factor Product Portfolio
        6.13.5 Amoytop Biotech Recent Developments/Updates
    6.14 Jiuyuan Gene Engineering
        6.14.1 Jiuyuan Gene Engineering Corporation Information
        6.14.2 Jiuyuan Gene Engineering Human Granulocyte Colony-stimulating Factor Description and Business Overview
        6.14.3 Jiuyuan Gene Engineering Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2017-2022)
        6.14.4 Jiuyuan Gene Engineering Human Granulocyte Colony-stimulating Factor Product Portfolio
        6.14.5 Jiuyuan Gene Engineering Recent Developments/Updates
    6.15 Four Rings Biopharmaceutical
        6.15.1 Four Rings Biopharmaceutical Corporation Information
        6.15.2 Four Rings Biopharmaceutical Human Granulocyte Colony-stimulating Factor Description and Business Overview
        6.15.3 Four Rings Biopharmaceutical Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2017-2022)
        6.15.4 Four Rings Biopharmaceutical Human Granulocyte Colony-stimulating Factor Product Portfolio
        6.15.5 Four Rings Biopharmaceutical Recent Developments/Updates
7 Human Granulocyte Colony-stimulating Factor Manufacturing Cost Analysis
    7.1 Human Granulocyte Colony-stimulating Factor Key Raw Materials Analysis
       7.1.1 Key Raw Materials
       7.1.2 Key Suppliers of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
    7.3 Manufacturing Process Analysis of Human Granulocyte Colony-stimulating Factor
    7.4 Human Granulocyte Colony-stimulating Factor Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
    8.1 Marketing Channel
    8.2 Human Granulocyte Colony-stimulating Factor Distributors List
    8.3 Human Granulocyte Colony-stimulating Factor Customers
9 Human Granulocyte Colony-stimulating Factor Market Dynamics
    9.1 Human Granulocyte Colony-stimulating Factor Industry Trends
    9.2 Human Granulocyte Colony-stimulating Factor Market Drivers
    9.3 Human Granulocyte Colony-stimulating Factor Market Challenges
    9.4 Human Granulocyte Colony-stimulating Factor Market Restraints
10 Global Market Forecast
    10.1 Human Granulocyte Colony-stimulating Factor Market Estimates and Projections by Type
        10.1.1 Global Forecasted Sales of Human Granulocyte Colony-stimulating Factor by Type (2023-2028)
        10.1.2 Global Forecasted Revenue of Human Granulocyte Colony-stimulating Factor by Type (2023-2028)
    10.2 Human Granulocyte Colony-stimulating Factor Market Estimates and Projections by Application
        10.2.1 Global Forecasted Sales of Human Granulocyte Colony-stimulating Factor by Application (2023-2028)
        10.2.2 Global Forecasted Revenue of Human Granulocyte Colony-stimulating Factor by Application (2023-2028)
    10.3 Human Granulocyte Colony-stimulating Factor Market Estimates and Projections by Region
        10.3.1 Global Forecasted Sales of Human Granulocyte Colony-stimulating Factor by Region (2023-2028)
        10.3.2 Global Forecasted Revenue of Human Granulocyte Colony-stimulating Factor by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
    12.1 Methodology/Research Approach
        12.1.1 Research Programs/Design
        12.1.2 Market Size Estimation
        12.1.3 Market Breakdown and Data Triangulation
    12.2 Data Source
        12.2.1 Secondary Sources
        12.2.2 Primary Sources
    12.3 Author List
    12.4 Disclaimer

List of Tables
    Table 1. Global Human Granulocyte Colony-stimulating Factor Sales Growth Rate Comparison by Type (2022-2028) & (K Dose) & (US$ Million)
    Table 2. Global Human Granulocyte Colony-stimulating Factor Sales Growth Rate Comparison by Application (2022-2028) & (K Dose) & (US$ Million)
    Table 3. Global Human Granulocyte Colony-stimulating Factor Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
    Table 4. Global Human Granulocyte Colony-stimulating Factor Market Competitive Situation by Manufacturers in 2021
    Table 5. Global Human Granulocyte Colony-stimulating Factor Sales (K Dose) of Key Manufacturers (2017-2022)
    Table 6. Global Human Granulocyte Colony-stimulating Factor Sales Market Share by Manufacturers (2017-2022)
    Table 7. Global Human Granulocyte Colony-stimulating Factor Revenue (US$ Million) by Manufacturers (2017-2022)
    Table 8. Global Human Granulocyte Colony-stimulating Factor Revenue Share by Manufacturers (2017-2022)
    Table 9. Global Market Human Granulocyte Colony-stimulating Factor Average Price (USD/Dose) of Key Manufacturers (2017-2022)
    Table 10. Manufacturers Human Granulocyte Colony-stimulating Factor Manufacturing Sites and Area Served
    Table 11. Manufacturers Human Granulocyte Colony-stimulating Factor Product Type
    Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 13. Global Human Granulocyte Colony-stimulating Factor by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Human Granulocyte Colony-stimulating Factor as of 2021)
    Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 15. Global Human Granulocyte Colony-stimulating Factor Sales by Region (2017-2022) & (K Dose)
    Table 16. Global Human Granulocyte Colony-stimulating Factor Sales Market Share by Region (2017-2022)
    Table 17. Global Human Granulocyte Colony-stimulating Factor Revenue by Region (2017-2022) & (US$ Million)
    Table 18. Global Human Granulocyte Colony-stimulating Factor Revenue Market Share by Region (2017-2022)
    Table 19. North America Human Granulocyte Colony-stimulating Factor Sales by Country (2017-2022) & (K Dose)
    Table 20. North America Human Granulocyte Colony-stimulating Factor Sales Market Share by Country (2017-2022)
    Table 21. North America Human Granulocyte Colony-stimulating Factor Revenue by Country (2017-2022) & (US$ Million)
    Table 22. North America Human Granulocyte Colony-stimulating Factor Revenue Market Share by Country (2017-2022)
    Table 23. Europe Human Granulocyte Colony-stimulating Factor Sales by Country (2017-2022) & (K Dose)
    Table 24. Europe Human Granulocyte Colony-stimulating Factor Sales Market Share by Country (2017-2022)
    Table 25. Europe Human Granulocyte Colony-stimulating Factor Revenue by Country (2017-2022) & (US$ Million)
    Table 26. Europe Human Granulocyte Colony-stimulating Factor Revenue Market Share by Country (2017-2022)
    Table 27. Asia Pacific Human Granulocyte Colony-stimulating Factor Sales by Region (2017-2022) & (K Dose)
    Table 28. Asia Pacific Human Granulocyte Colony-stimulating Factor Sales Market Share by Region (2017-2022)
    Table 29. Asia Pacific Human Granulocyte Colony-stimulating Factor Revenue by Region (2017-2022) & (US$ Million)
    Table 30. Asia Pacific Human Granulocyte Colony-stimulating Factor Revenue Market Share by Region (2017-2022)
    Table 31. Latin America Human Granulocyte Colony-stimulating Factor Sales by Country (2017-2022) & (K Dose)
    Table 32. Latin America Human Granulocyte Colony-stimulating Factor Sales Market Share by Country (2017-2022)
    Table 33. Latin America Human Granulocyte Colony-stimulating Factor Revenue by Country (2017-2022) & (US$ Million)
    Table 34. Latin America Human Granulocyte Colony-stimulating Factor Revenue Market Share by Country (2017-2022)
    Table 35. Middle East and Africa Human Granulocyte Colony-stimulating Factor Sales by Country (2017-2022) & (K Dose)
    Table 36. Middle East and Africa Human Granulocyte Colony-stimulating Factor Sales Market Share by Country (2017-2022)
    Table 37. Middle East and Africa Human Granulocyte Colony-stimulating Factor Revenue by Country (2017-2022) & (US$ Million)
    Table 38. Middle East and Africa Human Granulocyte Colony-stimulating Factor Revenue Market Share by Country (2017-2022)
    Table 39. Global Human Granulocyte Colony-stimulating Factor Sales by Type (2017-2022) & (K Dose)
    Table 40. Global Human Granulocyte Colony-stimulating Factor Sales Market Share by Type (2017-2022)
    Table 41. Global Human Granulocyte Colony-stimulating Factor Revenue by Type (2017-2022) & (US$ Million)
    Table 42. Global Human Granulocyte Colony-stimulating Factor Revenue Share by Type (2017-2022)
    Table 43. Global Human Granulocyte Colony-stimulating Factor Price by Type (2017-2022) & (USD/Dose)
    Table 44. Global Human Granulocyte Colony-stimulating Factor Sales (K Dose) by Application (2017-2022)
    Table 45. Global Human Granulocyte Colony-stimulating Factor Sales Market Share by Application (2017-2022)
    Table 46. Global Human Granulocyte Colony-stimulating Factor Revenue by Application (2017-2022) & (US$ Million)
    Table 47. Global Human Granulocyte Colony-stimulating Factor Revenue Share by Application (2017-2022)
    Table 48. Global Human Granulocyte Colony-stimulating Factor Price by Application (2017-2022) & (USD/Dose)
    Table 49. Chugai Pharmaceutical Corporation Information
    Table 50. Chugai Pharmaceutical Description and Business Overview
    Table 51. Chugai Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 52. Chugai Pharmaceutical Human Granulocyte Colony-stimulating Factor Product
    Table 53. Chugai Pharmaceutical Recent Developments/Updates
    Table 54. Kyowa Hakko Kirin Corporation Information
    Table 55. Kyowa Hakko Kirin Description and Business Overview
    Table 56. Kyowa Hakko Kirin Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 57. Kyowa Hakko Kirin Human Granulocyte Colony-stimulating Factor Product
    Table 58. Kyowa Hakko Kirin Recent Developments/Updates
    Table 59. Sanway Corporation Information
    Table 60. Sanway Description and Business Overview
    Table 61. Sanway Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 62. Sanway Human Granulocyte Colony-stimulating Factor Product
    Table 63. Sanway Recent Developments/Updates
    Table 64. GenSci Corporation Information
    Table 65. GenSci Description and Business Overview
    Table 66. GenSci Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 67. GenSci Human Granulocyte Colony-stimulating Factor Product
    Table 68. GenSci Recent Developments/Updates
    Table 69. SL PHARM Corporation Information
    Table 70. SL PHARM Description and Business Overview
    Table 71. SL PHARM Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 72. SL PHARM Human Granulocyte Colony-stimulating Factor Product
    Table 73. SL PHARM Recent Developments/Updates
    Table 74. Kexing Bioproducts Corporation Information
    Table 75. Kexing Bioproducts Description and Business Overview
    Table 76. Kexing Bioproducts Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 77. Kexing Bioproducts Human Granulocyte Colony-stimulating Factor Product
    Table 78. Kexing Bioproducts Recent Developments/Updates
    Table 79. Qilu Pharmaceutical Corporation Information
    Table 80. Qilu Pharmaceutical Description and Business Overview
    Table 81. Qilu Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 82. Qilu Pharmaceutical Human Granulocyte Colony-stimulating Factor Product
    Table 83. Qilu Pharmaceutical Recent Developments/Updates
    Table 84. CSPC Corporation Information
    Table 85. CSPC Description and Business Overview
    Table 86. CSPC Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 87. CSPC Human Granulocyte Colony-stimulating Factor Product
    Table 88. CSPC Recent Developments/Updates
    Table 89. Wuzhong Pharmaceutical Corporation Information
    Table 90. Wuzhong Pharmaceutical Description and Business Overview
    Table 91. Wuzhong Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 92. Wuzhong Pharmaceutical Human Granulocyte Colony-stimulating Factor Product
    Table 93. Wuzhong Pharmaceutical Recent Developments/Updates
    Table 94. Quangang Pharmaceutical Corporation Information
    Table 95. Quangang Pharmaceutical Description and Business Overview
    Table 96. Quangang Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 97. Quangang Pharmaceutical Human Granulocyte Colony-stimulating Factor Product
    Table 98. Quangang Pharmaceutical Recent Developments/Updates
    Table 99. Huabei Pharmaceutical Corporation Information
    Table 100. Huabei Pharmaceutical Description and Business Overview
    Table 101. Huabei Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 102. Huabei Pharmaceutical Human Granulocyte Colony-stimulating Factor Product
    Table 103. Huabei Pharmaceutical Recent Developments/Updates
    Table 104. Harbin Pharmaceutical Corporation Information
    Table 105. Harbin Pharmaceutical Description and Business Overview
    Table 106. Harbin Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 107. Harbin Pharmaceutical Human Granulocyte Colony-stimulating Factor Product
    Table 108. Harbin Pharmaceutical Recent Developments/Updates
    Table 109. Amoytop Biotech Corporation Information
    Table 110. Amoytop Biotech Description and Business Overview
    Table 111. Amoytop Biotech Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 112. Amoytop Biotech Human Granulocyte Colony-stimulating Factor Product
    Table 113. Amoytop Biotech Recent Developments/Updates
    Table 114. Jiuyuan Gene Engineering Corporation Information
    Table 115. Jiuyuan Gene Engineering Description and Business Overview
    Table 116. Jiuyuan Gene Engineering Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 117. Jiuyuan Gene Engineering Human Granulocyte Colony-stimulating Factor Product
    Table 118. Jiuyuan Gene Engineering Recent Developments/Updates
    Table 119. Four Rings Biopharmaceutical Corporation Information
    Table 120. Four Rings Biopharmaceutical Description and Business Overview
    Table 121. Four Rings Biopharmaceutical Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 122. Four Rings Biopharmaceutical Human Granulocyte Colony-stimulating Factor Product
    Table 123. Four Rings Biopharmaceutical Recent Developments/Updates
    Table 124. Production Base and Market Concentration Rate of Raw Material
    Table 125. Key Suppliers of Raw Materials
    Table 126. Human Granulocyte Colony-stimulating Factor Distributors List
    Table 127. Human Granulocyte Colony-stimulating Factor Customers List
    Table 128. Human Granulocyte Colony-stimulating Factor Market Trends
    Table 129. Human Granulocyte Colony-stimulating Factor Market Drivers
    Table 130. Human Granulocyte Colony-stimulating Factor Market Challenges
    Table 131. Human Granulocyte Colony-stimulating Factor Market Restraints
    Table 132. Global Human Granulocyte Colony-stimulating Factor Sales Forecast by Type (2023-2028) & (K Dose)
    Table 133. Global Human Granulocyte Colony-stimulating Factor Sales Market Share Forecast by Type (2023-2028)
    Table 134. Global Human Granulocyte Colony-stimulating Factor Revenue Forecast by Type (2023-2028) & (US$ Million)
    Table 135. Global Human Granulocyte Colony-stimulating Factor Revenue Market Share Forecast by Type (2023-2028)
    Table 136. Global Human Granulocyte Colony-stimulating Factor Sales Forecast by Application (2023-2028) & (K Dose)
    Table 137. Global Human Granulocyte Colony-stimulating Factor Sales Market Share Forecast by Application (2023-2028)
    Table 138. Global Human Granulocyte Colony-stimulating Factor Revenue Forecast by Application (2023-2028) & (US$ Million)
    Table 139. Global Human Granulocyte Colony-stimulating Factor Revenue Market Share Forecast by Application (2023-2028)
    Table 140. Global Human Granulocyte Colony-stimulating Factor Sales Forecast by Region (2023-2028) & (K Dose)
    Table 141. Global Human Granulocyte Colony-stimulating Factor Sales Market Share Forecast by Region (2023-2028)
    Table 142. Global Human Granulocyte Colony-stimulating Factor Revenue Forecast by Region (2023-2028) & (US$ Million)
    Table 143. Global Human Granulocyte Colony-stimulating Factor Revenue Market Share Forecast by Region (2023-2028)
    Table 144. Research Programs/Design for This Report
    Table 145. Key Data Information from Secondary Sources
    Table 146. Key Data Information from Primary Sources
List of Figures
    Figure 1. Product Picture of Human Granulocyte Colony-stimulating Factor
    Figure 2. Global Human Granulocyte Colony-stimulating Factor Market Share by Type in 2021 & 2028
    Figure 3. 300μg/Dose Product Picture
    Figure 4. 150μg/Dose Product Picture
    Figure 5. 75μg/Dose Product Picture
    Figure 6. Others Product Picture
    Figure 7. Global Human Granulocyte Colony-stimulating Factor Market Share by Application in 2021 & 2028
    Figure 8. Hospital
    Figure 9. Clinic
    Figure 10. Global Human Granulocyte Colony-stimulating Factor Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 11. Global Human Granulocyte Colony-stimulating Factor Market Size (2017-2028) & (US$ Million)
    Figure 12. Global Human Granulocyte Colony-stimulating Factor Sales (2017-2028) & (K Dose)
    Figure 13. Human Granulocyte Colony-stimulating Factor Sales Share by Manufacturers in 2021
    Figure 14. Global Human Granulocyte Colony-stimulating Factor Revenue Share by Manufacturers in 2021
    Figure 15. The Global 5 and 10 Largest Human Granulocyte Colony-stimulating Factor Players: Market Share by Revenue in 2021
    Figure 16. Human Granulocyte Colony-stimulating Factor Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
    Figure 17. Global Human Granulocyte Colony-stimulating Factor Sales Market Share by Region (2017-2022)
    Figure 18. Global Human Granulocyte Colony-stimulating Factor Sales Market Share by Region in 2021
    Figure 19. Global Human Granulocyte Colony-stimulating Factor Revenue Market Share by Region (2017-2022)
    Figure 20. Global Human Granulocyte Colony-stimulating Factor Revenue Market Share by Region in 2021
    Figure 21. U.S. Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 22. Canada Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 23. Germany Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 24. France Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 25. U.K. Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 26. Italy Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 27. Russia Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 28. China Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 29. Japan Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 30. South Korea Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 31. India Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 32. Australia Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 33. Taiwan Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 34. Indonesia Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 35. Thailand Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 36. Malaysia Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 37. Philippines Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 38. Vietnam Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 39. Mexico Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 40. Brazil Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 41. Argentina Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 42. Turkey Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 43. Saudi Arabia Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 44. UAE Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 45. Sales Market Share of Human Granulocyte Colony-stimulating Factor by Type (2017-2022)
    Figure 46. Manufacturing Cost Structure of Human Granulocyte Colony-stimulating Factor
    Figure 47. Manufacturing Process Analysis of Human Granulocyte Colony-stimulating Factor
    Figure 48. Human Granulocyte Colony-stimulating Factor Industrial Chain Analysis
    Figure 49. Channels of Distribution
    Figure 50. Distributors Profiles
    Figure 51. Bottom-up and Top-down Approaches for This Report
    Figure 52. Data Triangulation
    Figure 53. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Chugai Pharmaceutical
Kyowa Hakko Kirin
Sanway
GenSci
SL PHARM
Kexing Bioproducts
Qilu Pharmaceutical
CSPC
Wuzhong Pharmaceutical
Quangang Pharmaceutical
Huabei Pharmaceutical
Harbin Pharmaceutical
Amoytop Biotech
Jiuyuan Gene Engineering
Four Rings Biopharmaceutical
Frequently Asked Questions
Human Granulocyte Colony-stimulating Factor report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Human Granulocyte Colony-stimulating Factor report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Human Granulocyte Colony-stimulating Factor report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Cilastatin Sodium

The research report includes specific segments by region (country), by company, by Type and by Ap ... Read More

Ophthalmic Solution

The research report includes specific segments by region (country), by company, by Type and by Ap ... Read More